Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurogenic Orthostatic Hypotension Clear all
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 28, 2026, 7:28 AM EDT
Terminated Phase 4 Interventional

A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension

NCT00046163
View directory record Official record
Conditions
Hypotension, Orthostatic
Interventions
midodrine hydrochloride (ProAmatine®)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
St. Petersburg, Florida • Upland, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

A Study for Patients With Neurogenic Orthostatic Hypotension

NCT00046475
View directory record Official record
Conditions
Hypotension, Orthostatic
Interventions
Midodrine Hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
15
States / cities
Huntsville, Alabama • Miramar, Florida • St. Petersburg, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 28, 2026, 7:28 AM EDT
Withdrawn Not applicable Interventional

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

NCT04976101
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension
Interventions
Sinosuidal Galvanic Vestibular Stimulation, Placebo
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 28, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830
View directory record Official record
Conditions
Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Interventions
Accelerometer, placebo pill, Midodrine or atomoxetine pill
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 7:28 AM EDT
Completed No phase listed Observational

Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension

NCT01316666
View directory record Official record
Conditions
Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension

NCT00004268
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
midodrine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 28, 2026, 7:28 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT03567447
View directory record Official record
Conditions
Parkinson Disease, Falls Patient
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Early Phase 1 Interventional Results available

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

NCT04620382
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Interventions
Midodrine, Placebo pill, Abdominal compression, sham compression
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury

NCT03602014
View directory record Official record
Conditions
Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
Interventions
Northera, Placebo
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Droxidopa in Treating Patients With Neurogenic Hypotension

NCT00004478
View directory record Official record
Conditions
Shy-Drager Syndrome, Orthostatic Hypotension
Interventions
droxidopa
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Sep 28, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 28, 2026, 7:28 AM EDT
Recruiting No phase listed Observational

Natural History Study of Synucleinopathies

NCT01799915
View directory record Official record
Conditions
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 28, 2026, 7:28 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions
Ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

NCT02705755
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 28, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

NCT01927055
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 28, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

CPAP for the Treatment of Supine Hypertension

NCT05489575
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions
Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position
Device · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03829657
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes

NCT04858178
View directory record Official record
Conditions
Spinal Cord Injuries, Autonomic Imbalance, Autonomic Dysreflexia, Orthostatic; Hypotension, Neurogenic
Interventions
Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia, Transcutaneous spinal cord stimulation
Diagnostic Test · Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

NCT02586623
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 28, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

NCT02784535
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 28, 2026, 7:28 AM EDT